Crown Bioscience, a leading global contract research organization (CRO) based in the United States and a part of JSR Life Sciences and Japan’s JSR Corporation, has been awarded the prestigious 2024 Fierce CRO Award for Excellence in Client Service and Partnership. This annual accolade, presented by Fierce Biotech, recognizes top CROs that demonstrate exceptional innovation, leadership, and commitment to advancing drug development through collaborative client relationships. Crown Bioscience’s dedication to excellence, transparency, and innovation has earned it a prominent place among industry leaders.
The Fierce CRO Awards celebrate organizations that excel in fostering strong partnerships and delivering outstanding client experiences. Recipients are chosen for their ability to go beyond conventional expectations, offering tailored solutions and achieving exceptional results for life sciences companies. Crown Bioscience’s recognition in this category highlights its consistent focus on meeting and exceeding the needs of its clients, setting a benchmark for the industry.
“Winning this award is a true testament to our team’s dedication to going above and beyond for our clients,” stated Dr. Jonny McMichael, Vice President of Client Experience and Enablement at Crown Bioscience. “We aim to accelerate the journey of new therapies by collaborating closely with our partners across the drug development continuum.”
Crown Bioscience has built a reputation for excellence through its innovative preclinical research capabilities, which help pharmaceutical and biotech companies advance their drug development pipelines. A key differentiator for Crown Bioscience is its Customer Satisfaction Program, a unique initiative designed to capture unfiltered client feedback and measure satisfaction across various aspects of service delivery. The program ensures that client voices are heard and integrated into the company’s processes, fostering continuous improvement and accountability.
In addition to its focus on client satisfaction, Crown Bioscience emphasizes transparency in communication and operational processes. These efforts have solidified its position as a trusted partner for clients worldwide, enabling it to establish and maintain long-term relationships built on mutual trust and shared success.
Dr. McMichael elaborated on the company’s approach, stating, “This recognition motivates us to continue raising the bar for the CRO industry. We are thankful to our entire team for making Crown Bioscience a trusted, client-focused partner in the mission to bring new treatments to patients faster and more efficiently.”
Crown Bioscience’s achievements reflect its broader mission to support life sciences companies in overcoming complex challenges in drug development. By providing cutting-edge preclinical models, advanced analytics, and expert scientific guidance, the company empowers its clients to make informed decisions and accelerate timelines for bringing innovative therapies to market.
As part of JSR Life Sciences, Crown Bioscience benefits from access to a global network of resources and expertise. This affiliation allows the company to remain at the forefront of scientific innovation while delivering high-quality services tailored to client needs. Crown Bioscience’s commitment to excellence aligns with JSR Corporation’s broader vision of advancing healthcare through innovation and collaboration.
The 2024 Fierce CRO Award serves as a significant milestone in Crown Bioscience’s journey, reinforcing its standing as a leader in the CRO industry. The award also underscores the critical role of CROs in accelerating the development of life-saving therapies and addressing unmet medical needs. Crown Bioscience’s recognition is a testament to its ability to combine scientific expertise, operational excellence, and a deep commitment to client success.
The full Fierce CRO Awards report, which includes detailed profiles of all the winners, is available on Fierce Biotech’s website. This report provides insights into the achievements of leading CROs and their contributions to the life sciences industry.
